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Correlation of sensitizing capacity and T-cell recognition
within the Bet v 1 family
Claudia Kitzm€uller, PhD,a,b Nora Zulehner, MSc,b Anargyros Roulias, MSc,c Peter Briza, PhD,c Fatima Ferreira, PhD,c,d
Ingrid Fae, MSc,e Gottfried F. Fischer, MD,e and Barbara Bohle, PhDa,b Vienna and Salzburg, AustriaBackground: Bet v 1 is the main sensitizing allergen in birch
pollen. Like many other major allergens, it contains an
immunodominant T cell–activating region (Bet v 1142-156). Api g
1, the Bet v 1 homolog in celery, lacks the ability to sensitize and
is devoid of major T-cell epitopes.
Objective: We analyzed the T-cell epitopes of Mal d 1, the
nonsensitizing Bet v 1 homolog in apple, and assessed possible
differences in uptake and antigen processing of Bet v 1, Api g 1, and
Mal d 1.
Methods: For epitope mapping, Mal d 1–specific T-cell lines were
stimulated with overlapping synthetic 12-mer peptides. The
surface binding, internalization, and intracellular degradation of
Bet v 1, Api g 1, and Mal d 1 by antigen-presenting cells were
compared by using flow cytometry. All proteins were digested
with endolysosomal extracts, and the resulting peptides were
identified by means of mass spectrometry. The binding of Bet v
1142-156 and the homologous region in Mal d 1 by HLA class II
molecules was analyzed in silico.
Results: Like Api g 1, Mal d 1 lacked dominant T-cell epitopes.
The degree of surface binding and the kinetics of uptake and
endolysosomal degradation of Bet v 1, Api g 1, and Mal d 1 were
comparable. Endolysosomal degradation of Bet v 1 and Mal d 1
resulted in very similar fragments. The Bet v 1142-156 and Mal
d 1141-155 regions showed no striking difference in their binding
affinities to the most frequent HLA-DR alleles.
Conclusion: The sensitizing activity of different Bet v 1
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In patients with IgE-mediated allergy, the full manifestation of
symptoms is preceded by a sensitization phase in which antigen-
presenting cells (APCs) take up allergens and degrade them in
endosomes/lysosomes. The generated peptides are then trans-
ferred into exocytic vesicles, where they bind to HLA class II
molecules. HLA/peptide complexes are transported to the plasma
membrane, where they can be recognized by T cells through their
T-cell receptor.1 In atopic subjects the cytokine milieu during pre-
sentation favors the development of naive T cells into TH2 cells,
2-4
which in turn produce cytokines that lead to immunoglobulin
class-switching in B cells and the production of allergen-
specific IgE.5 The latter is bound to high-affinity receptors on
effector cells, so that on each subsequent contact, sensitized sub-
jects can have allergic symptoms to the respective allergens.
One of the most common causes of IgE-mediated allergy in
Northern and Central Europe and North America is birch pollen.
Its main sensitizing allergen is Bet v 1, to which 93% of patients
with birch pollen allergy have specific IgE.6 Homologs of Bet v 1
have been identified in awide range of foods7; they show sequence
similarities of 50% to 80% and share a tertiary structure called the
Bet v 1 fold.8With the exception ofDau c 1 fromcarrot9,10 andCor
a 1 from hazelnut,11,12 Bet v 1–related food allergens are consid-
ered to be unable to initiate sensitization in atopic subjects. How-
ever, because of IgEcross-reactivity, they cause immediate allergic
symptoms in more than 70% of Bet v 1–sensitized patients.6
It is still not known which properties make a protein allergenic.
For Bet v 113 and other major allergens, such as Der p 1 and Der p
2 from house dust mite,14,15 Ves v 5 from wasp venom,16 Art v 1
from mugwort,17 Amb a 1 from ragweed,18 Hev b 6.01 from la-
tex,19 Cry j 1 and Cry j 2 from Japanese cedar,20 Pru p 3 from
peach,21-23 Fel d 1 from cat,24 or Equ c 1 from horse,25 it has
been shown that they contain 1 or more immunodominant T-
cell epitopes recognized by more than 50% of allergic patients.
However, the nonsensitizing Bet v 1 homolog from celery, Api
g 1, is devoid of frequently recognized T-cell epitopes.26 Hence
the presence of immunodominant T cell–activating regions might
be an intrinsic feature of sensitizing allergens.
To further elucidate this hypothesis, we analyzed the T-cell
epitopes ofMal d 1, another highly homologous but nonsensitizing
Bet v1–related protein in apple.27Toassesswhether the presenceor
absence of an immunodominant T cell–activating region depends
on antigen processing and presentation, we used recombinant Bet151
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We studied their internalization by different APCs from human
blood. Furthermore, we followed these proteins through the
endocytic pathway in monocyte-derived dendritic cells (mdDCs)
and analyzed their degradation both in mdDCs and by endolyso-
somal extracts derived from mdDCs. Finally, we compared the
binding affinities of T-cell epitopes derived from Bet v 1 and Mal
d 1 to MHC class II molecules in silico.
METHODS
Patients and allergens
Twelve patients with birch pollen allergy had typical case histories, positive
skin prick test responses to birch pollen extract (ALK-Abello, Hørsholm,
Denmark), and birch pollen–specific IgE levels of greater than 3.5 kUA/L (Im-
munoCAP; Thermo Fisher Scientific, Uppsala, Sweden). Patients with birch
pollen allergy with associated apple allergy additionally reported oral allergy
syndrome to apple. Bet v 1– and Mal d 1–specific IgE levels were determined
by using ImmunoCAP. HLA-DRB and HLA-DQB1 typing was performed
with a commercial sequence-specific oligonucleotide typing kit (Histo Spot
SSO HLA-DRB and HLA-DQB1 typing kit; BAG Healthcare, Lich Ger-
many). Samples with only a single detectable HLA-DRB1 or HLA-DQB1
allele were also typed by using sequence-specific primers (All Set SSP DRB
and DQB1 low resolution; Olerup, Vienna, Austria). High-resolution typing
was performed by means of nucleotide sequencing (SeCore Invitrogen, Life
Technology, Brown Deer, Wis).
Three included nonallergic donors had no case history of early spring
pollinosis and no Bet v 1–specific IgE. The study was approved by the local
ethics committee. Donors provided written informed consent.
Recombinant Bet v 1.0101 (Bet v 1), Api g 1.0101 (Api g 1), and Mal
d 1.0108 (Mal d 1) were purchased from Biomay (Vienna, Austria). These
proteins were produced in Escherichia coli and contained less than 20 EU
LPS/mg of protein. Their IgE binding was demonstrated in ELISAs and im-
munoblots (data not shown). Proteins were conjugated to pHrodo succini-
midyl ester, fluorescein isothiocyanate (FITC)–succinimidyl ester, and
Alexa Fluor 488–succinimidyl ester (all from Invitrogen, Carlsbad, Calif), ac-
cording to the manufacturer’s instructions.
The degree of labeling (DOL; moles of dye per mole of protein) was
determined by using a NanoDrop ND-1000 (NanoDrop Technologies,
Wilmington, Del) and the following equation:
DOL5
Abslmax Dye
εDye3 protein concentration ðMÞ
(lmax pHrodo 5 560 nm, lmax Alexa Fluor 488 5 494 nm, εpHrodo 5 65,000
cm21M21, εAlexa488 5 71,000 cm
21Mol21).
The DOLs for pHrodo and for Alexa Fluor 488 of Api g 1 were only about a
third of the DOLs of Bet v 1 and Mal d 1, probably because of the lower
number of lysine residues in its primary structure.
Cell preparation
PBMCs were isolated from peripheral blood by using Ficoll-Hypaque
(Pharmacia, Uppsala, Sweden) density gradient centrifugation. Monocytes wereisolated from PBMCs by using immunomagnetic cell sorting (MACS; Miltenyi
Biotec,BergischGladbach,Germany), resulting ingreater than95%CD141 cells.
mdDCs and microsomes thereof were generated, as described previously.28-30Epitope mapping of Mal d 1–specific T-cell lines
Mal d 1–specific T-cell lines (TCLs) were generated from PBMCs (1.5 3
106 per well) by using 10 mg/mLMal d 1, as previously described.31 Cultures
without Mal d 1 served as controls. After 5 days, suboptimal doses of human
rIL-2 (10 U/mL; Boehringer, Mannheim, Germany) were added. At day 7,
T-cell blasts were harvested by using density gradient centrifugation and
expanded with irradiated PBMCs and IL-2. Ten days after the last feeding,
TCLswere stimulated in duplicateswith 13 105 irradiated (60Gy) autologous
PBMCs plus either Bet v 1,Mal d 1 (5mg/mL), or 49 overlapping synthetic 12-
mer peptides (each 5 mg/mL; Intavis, K€oln, Germany), representing the com-
plete amino acid (aa) sequence ofMal d 1. The latex allergenHev b 3 served as
a negative control. Incorporation of tritiated thymidine was measured after 48
hours. Stimulation indiceswere calculated as the ratio between counts permin-
ute obtained in cultures with T cells plus autologous PBMCs plus peptide and
counts per minute obtained in cultures containing T cells and PBMCs alone.
A stimulation index of 2.5 was defined as positive T-cell proliferation.Flow cytometry
The following mAbs were used: CD14–peridinin-chlorophyll-protein,
CD19-allophycocyanin (BD Biosciences, San Jose, Calif), CD1c-
allophycocyanin, CD141-allophycocyanin, and CD303-phycoerythrin (Mil-
tenyi Biotec). Isotype controls were used to detect nonspecific binding. Flow
cytometry was performed with a FACSCanto II (BD Biosciences) and
analyzed with FACSDiva software (BD Biosciences) and FlowJo software
(TreeStar, Ashland, Ore).Surface binding, endocytosis, and degradation of
labeled proteins
Alexa Fluor 488–labeled proteins (400 ng/mL) were incubated with
freshly isolated PBMCs (2 3 106) for 1 hour at 48C, washed, transferred to
378C for another 20 hours, and labeled with cell type–specific surface
markers to assess protein uptake. mdDCs (1 3 106) were incubated with
Alexa Fluor 488–labeled proteins (400 ng/mL) for 3 hours at 48C, washed,
and fixed in 2% paraformaldehyde to assess surface binding. mdDCs (2 3
105) were incubated with pHrodo-labeled proteins (3 mg/mL) for 1 hour at
48C, washed, and further incubated at 378C in fresh medium and analyzed
at the indicated time points to determine endocytosis. mdDCs (1 3 106)
were incubated with FITC-labeled proteins (15 mg/mL) and incubated for
3 hours at 378C, washed, and further incubated at 378C for the indicated
time periods to assess intracellular degradation. The percentage of antigen
degradation is represented as the ratio of FITC1 cells at the indicated time
to FITC1 cells at 0 hours.Degradome assays
Allergens (5 mg each) were digested with microsomal enzymes (7 mg)
isolated from mdDCs, as described previously.28 Reactions were stopped at
indicated time points by using heat denaturation and analyzed by means of
mass spectrometry with an ESI-QTOF mass spectrometer fitted with a capil-
lary rpHPLC (Waters, Milford, Mass).HLA-DR–binding predictions
MHC class II–binding predictions were performed with the homologous
15-mer peptides Bet v 1142-156 (TLLRAVESYLLAHSD) and Mal d 1141-155
(GLFKLIESYLKDHPD) on August 20, 2014, by using the Immune Epitope
Database analysis resource Consensus tool (http://tools.immuneepitope.org/
mhcii/).32,33 Percentile ranks are generated by comparing the peptide’s score
with 15 million random 15-mers from SWISSPROT database; a small percen-
tile rank indicates high affinity.
TABLE I. Characteristics of patients with birch pollen allergy
and associated apple allergy
Patient no.







1 4.7 3.5 07:01 11:01 3, 4 B1*02, *03
2 18.0 4.0 09:01 11:01 3, 4 B1*03
3 5.9 4.5 03:01 15:01 3, 5 B1*06, *02
4 3.9 1.2 07:01 11:01 3, 4 B1*02, *03
5 82.5 22.1 11:01 11:04 3 B1*03
6 34.7 16.1 11:04 13:01 3 B1*06, *03
7 80.2 19.6 01:01 11:01 3 B1*05, *03
8 12.2 6.2 07:01 13:01 3, 4 B1*06, *02
9 8.2 1.5 01:01 13:01 3 B1*03, *05
10 7.5 1.7 07:01 13:01 3, 4 B1*02, *06
11 22.3 3.5 07:01 14:05 3, 4 B1*05, *02
12 3.0 0.82 07:01 15:01 4, 5 B1*02, *06
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Data were analyzed with IBM SPSS 16.0 software (SPSS, Chicago,
Ill). Data from different patients were not normally distributed (Shapiro-
Wilk test) and therefore were presented as medians and interquartile
ranges. Statistical differences were determined by using the Wilcoxon
signed-rank test and considered statistically significant at a P value of less
than .05. Data from duplicate and triplicate experiments are shown as
means with SDs.FIG 1. T-cell epitope mapping of Mal d 1. Proliferation of Mal d 1–specific
TCLs from 12 different patients to 49 overlapping peptides spanning the aa
sequence of Mal d 1 is shown. Peptides inducing a stimulation index of
greater than 2.5 are denoted in black. Peptides matching the major T-cell
epitope Bet v 1142-156 are denoted in italics.RESULTS
T-cell epitopes of Mal d 1
Allergen-specific IgE levels and HLA phenotypes of the 12
patients with birch pollen allergy and associated apple allergy are
summarized in Table I. Mal d 1–specific TCLs generated from
these patients were stimulated with overlapping 12-mer peptides
representing the primary structure of Mal d 1 (Fig 1). Similar to
Api g 1,26 we could not identify any regions that were recognized
by more than 33% of TCLs. Four patients recognized the peptide
Mal d 11-12, and 3 patients recognized the peptides Mal d 167-78,
Mal d73-84, and Mal d 197-108. The peptides Mal d 14-15, Mal
d 125-36, Mal d 134-45, Mal d 137-48, Mal d 149-60, Mal d 152-63,
Mal d 158-69, Mal d 161-72, Mal d 170-81, Mal d 176-87, Mal
d 1142-153, and Mal d 1145-157 were recognized by 2 patients
each. Seventeen peptides stimulated a proliferative response in
only 1 patient (Mal d 17-18, Mal d 113-24, Mal d 122-33, Mal
d 128-39, Mal d 131-42, Mal d 146-57, Mal d 155-66, Mal d 182-93,
Mal d 188-99, Mal d 191-102, Mal d 194-105, Mal d 1109-120, Mal
d 1112-123, Mal d 1118-129, Mal d 1124-135, Mal d 1127-138, and
Mal d 1139-150). The peptides Mal d 110-21, Mal d 116-27, Mal
d 119-30, Mal d 140-51, Mal d 143-54, Mal d 164-75, Mal d 179-90,
Mal d 185-96, Mal d 1100-111, Mal d 1103-114, Mal d 1106-117, Mal
d 1115-126, Mal d 1121-132, Mal d 1130-141, Mal d 1133-144, and
Mal d 1136-147 did not induce proliferation in any of the TCLs.
Except for patients 2, 3, 9, and 10, all subjects recognized more
than 1 peptide.Uptake of Bet v 1, Api g 1, and Mal d 1 by different
types of APCs
First, we analyzed the uptake of recombinant proteins labeled
with Alexa Fluor 488 by different types of APCs in PBMCs frompatients with birch pollen allergy with associated food allergies
and nonallergic donors. Compared with Api g 1 and Mal d 1,
uptake of Bet v 1 was enhanced in monocytes (CD141), plasma-
cytoid dendritic cells (CD142CD3031), and the 2 types of
myeloid dendritic cells (mDCs; mDC1, CD1c1CD192; mDC2,
CD142CD1411)34 in patients with birch pollen allergy (Fig 2,
A). However, this increase could be caused by allergen-specific
IgE in the sera from allergic patients because no difference in
uptake of the 3 allergens was detected in nonallergic subjects
(Fig 2, B).
FIG 2. Uptake of allergens by APCs in human blood. PBMCs from donors with birch pollen allergy with
associated food allergies (A) or nonallergic donors (B)were incubated with Alexa Fluor 488–labeled Bet v 1,
Api g 1, or Mal d 1 for 1 hour at 48C; washed; and further incubated at 378C for 20 hours. The percentage of
Alexa Fluor 488–positive cell populations was determined by using flow cytometry (n5 3, mean6 SD). pDC,
Plasmacytoid dendritic cells.
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g 1, and Mal d 1 by mdDCs
To perform a more detailed analysis of the endocytosis and
subsequent processing of the different members of the Bet v 1
family, we used immature mdDCs, which can be obtained in
higher numbers than dendritic cells from peripheral blood.
mdDCs were incubated with Alexa Fluor 488–labeled allergens
for 3 hours at 48C for prevention of endocytosis to study the
surface binding of the allergens. Bet v 1 was bound by a slightly
higher percentage of mdDCs than Api g 1 and Mal d 1 (Fig 3, A);
however, the number of positive cells was generally extremely
low. To monitor the internalization of the allergens by mdDCs,
we labeled the proteins with pHrodo, which starts to emit bright
fluorescent light only when it reaches the acidic environment of
endosomes. We followed the protein uptake for up to 24 hours
and found no difference in internalization kinetics (Fig 3, B).
To assess intracellular degradation, we used FITC-conjugated al-
lergens and performed a pulse-chase experiment in which we first
loaded the cells with the allergens for 3 hours at 378C and subse-
quently monitored the disappearance of fluorescence. No differ-
ences in the degradation kinetics of the proteins were found
(Fig 3, C).Endolysosomal processing of Bet v 1, Api g 1, and
Mal d 1
Bet v 1, Api g 1, and Mal d 1 were incubated with microsomal
proteases isolated from mdDCs from allergic patients to learn
more about the peptides generated by means of endolysosomal
processing of the different allergens. At defined time intervals
(1, 3, 6, 12, 24, 36, and 48 hours) of lysosomal degradation,
proteolytic fragments of all allergens were identified by using
tandemmass spectrometry (Fig 4). Peptide clusters relating to the
regions Bet v 11-22, Bet v 123-36, Bet v 183-102, and Bet v 1146-157
appeared after 1 hour of proteolysis of either food allergen. After
3 hours, additional clusters related to Bet v 133-55, Bet v 156-65,
and Bet v 1103-115 were detected. In contrast, fragments matching
Bet v 166-80 were rarely detected in either food allergen. Peptide
clusters in the region Bet v 1116-127 appeared earlier on
degradation of both food allergens than of Bet v 1. Fragmentscorresponding to Bet v 1104-115 appeared in Api g 1 but not in
Mal d 1. Together, these data indicated a highly similar
endolysosomal processing of Bet v 1 and its dietary homologs.
In the immunodominant T cell–activating region Bet v 1142-156,
early fragments were found for Bet v 1 (Bet v 1146-157) and
Mal d 1 (Mal d 1145-158), whereas they were missing for Api g
1. As previously demonstrated for Bet v 1,28 all proteolytic
peptide clusters of the food allergens covered T cell–activating
regions identified by using epitope mapping (Fig 4).HLA class II binding affinity of Bet v 1142-156 and Mal
d 1141-155
Fig 4 shows that very similar peptide clusters were generated
by means of endolysosomal processing in the C-termini of Bet
v 1 and Mal d 1. Although Mal d 1141-155 shows an aa similarity
of 60% with the immunodominant region Bet v 1142-156, it was
recognized by less than 25% of the studied patients (Fig 1). Dif-
ferential loading of these peptides into HLA class II molecules
might be a reason for this observation. Thus we compared the
binding affinities of these peptides with those of the most frequent
HLA-DR alleles in European white subjects (HLA-DRB1*01:01,
*03:01, *04:01, *07:01, *11:01, *13:01, and *15:01)35,36 because
Bet v 1142-156 has been shown to be HLA-DR restricted
37 and to
bind promiscuously to several HLA-DR alleles.38 Apart from
some variations in the binding to individual alleles, we found
no general difference (Table II). Bet v 1142-156 had a lower percen-
tile rank for HLA-DRB1*03:01, *07:01, *13:01, and *15:01,
whereas Mal d 1141-155 had a lower percentile rank for HLA-
DRB1*01:01, *04:01, and *11:01.DISCUSSION
Major allergens from various sources contain immunodominant
T cell–activating regions13-25 recognized by allergen-specific
CD41 T lymphocytes from more than 50% of the respective
allergic subjects. Because T lymphocytes play a major role in
the initiation of allergic disorders, the distinct T-cell recognition
of allergens might account for their sensitizing activity. Indeed,
by comparing T-cell epitope mappings from highly homologous
FIG 3. Bet v 1, Api g 1, and Mal d 1 in the endocytic pathway. Surface binding (A), endocytosis (B), and
intracellular degradation (C) by mdDCs incubated with Bet v 1, Api g 1, or Mal d 1 conjugated to different
fluorophores are shown. Fig 3, A, Alexa Fluor 488–positive cells after 1 hour at 48C (n5 6). Fig 3, B, pHrodo-
positive cells after 1 hour at 48C and shift to 378C for indicated periods of time (n 5 5). Fig 3, C, Relative
percentage of FITC1 cells at indicated time points: cells after 3 hours at 378C (time point 0) were set to
100% (n 5 5).
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their sensitizing activity and the existence of dominant T-cell epi-
topes. Bet v 1, the major sensitizing protein in the Bet v 1 family,
contains the region Bet v 1142-156, which is recognized by 63% of
patients with birch pollen allergy.13 Cor a 1 in hazelnut contains
the region Cor a 1142-153, which is recognized by 47% of patients
with birch pollen allergy and concomitant hazelnut allergy.39 In
addition to its cross-reactivity with the major birch pollen
allergen,39 Cor a 1 has been reported to induce IgE production
independently of Bet v 1 in a low number of children with hazel-
nut allergy.12 Conversely, the allergic response to Api g 1 is
restricted to previous sensitization to Bet v 1, and no T-cell
epitope in the celery allergen was recognized by more than
33% of the studied subjects.26 Similarly, the allergic response to
Mal d 1, the most frequent trigger for birch pollen–related food
allergy,6 predominantly results from humoral and cellular cross-
reactivity with Bet v 1.27 In this work we mapped the T-cell epi-
topes of Mal d 1. Although Mal d 1 shows an overall sequence
similarity of 71% with Bet v 1, none of the 24 T-cell epitopes
found was recognized by more than 33% of the patients under
investigation (Fig 1).
Along these lines, we have obtained very similar results for
homologous members of another family of relevant plant-food
allergens (ie, nonspecific lipid transfer proteins [nsLTPs]). Study-
ing the cellular and humoral response to Pru p 3 and Cor a 8, therespective nsLTPs from peach and hazelnut, revealed that Pru p 3
was the original cause for sensitization to Cor a 8 in a group of
Italian patients with allergies to both foods.40 For Pru p 3, immu-
nodominant T-cell epitopes located within aa 12 to 27, aa 34 to 48,
and aa 57 to 80 were described,21-23 whereas Cor a 8 contained
none.40 Together, the identification of major T-cell epitopes solely
in sensitizing members of the Bet v 1 and nsLTP families indi-
cates that distinct T-cell recognition of an allergen might deter-
mine its sensitizing activity.
But why do highly homologous members from the same
protein family behave so differently in their T-cell reactivity?
Differences in antigen processing might partly answer this
question. Indeed, we previously found that Pru p 3 was more
stable to endolysosomal processing than Cor a 8,40 which is char-
acteristic for immunogenic proteins.41 Here we compared the
behavior of Bet v 1, Api g 1, and Mal d 1 in the major steps of an-
tigen processing, namely uptake, endolysosomal degradation, and
peptide loading to commonHLA class II molecules.We could not
identify obvious differences of the proteins in any of these pro-
cesses. These findings imply that in contrast to nsLTP, antigen
processing plays no role for the sensitizing activity of members
of the Bet v 1 family. However, we have used mdDCs as APCs.
Regarding the different routes of exposure to the different aller-
gens (ie, inhalant for Bet v 1 and gastrointestinal for its dietary ho-
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FIG 4. Endolysosomal processing of Bet v 1, Api g 1, and Mal d 1. Peptide sequences derived from Bet v 1,
Api g 1, andMal d 1 incubated with microsomal fractions frommdDCs for 1, 3, 6, 12, 24, 36, and 48 hours are
shown. Each line represents a unique peptide found. The immunodominant T cell–activating region Bet v
1142-156 is denoted in gray, and T-cell epitopes in Api g 1 and Mal d 1 are framed in the respective aa
sequence.
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TABLE II. Percentile ranks of binding to HLA-DR alleles
aa Region Sequence
Percentile ranks of binding to HLA-DR B1*
01:01 03:01 04:01 07:01 11:01 13:01 15:01
Bet v 1142-156 TLLRAVESYLLAHSD 6.71 6.68 10.51 9.14 8.05 5.02 0.4
Mal d 1141-155 GLFKLIESYLKDHPD 3.49 11.53 1.49 19.43 1.49 15.71 2.87
Percentile ranks as calculated by using the Immune Epitope Database analysis resource consensus tool. The lower percentile rank for each HLA-DR allele representing higher
binding affinity is shown in boldface. Identical aa residues are shown in boldface, and similar aa residues are shown in italics and underlined.
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gastrointestinal tract.
By means of direct comparison of the highly homologous
proteins Bet v 1 and Mal d 1 in the major steps of antigen
processing, we found no inherent characteristic of the pollen
allergen explaining the existence of the dominant T cell–
activating region Bet v 1142-156. The fact that the very similar re-
gion Mal d 1141-155 contained no relevant T-cell epitopes could
not be explained by a bias of HLA phenotypes in our study
cohort because several Mal d 1141-155–negative patients ex-
pressed HLA alleles predicted to bind this peptide with high af-
finity. However, using pure recombinant allergens, we omitted
other intrinsic features associated with allergenicity, such as
lipid binding and activation of Toll-like receptors or glycosyla-
tion and binding to C-type lectins, which might affect uptake
and endolysosomal degradation. Only recently, the natural
ligand for Bet v 1, quercetin-3-O-sophoroside, was identified.42
Bet v 1 ligand interaction generally enhances the volume of the
hydrophobic pocket and thereby alters the protein surface.43,44
Whether such structural changes influence the uptake and pro-
cessing of Bet v 1 is currently not known. Because quercetin is
abundant in apples, it might also bind to Mal d 1. Apart from
that, Bet v 1 and Mal d 1 might pass differently through the nasal
and oral mucosa, respectively. Therefore our future studies will
also address their passage through the respective epithelial
barriers.
We thank Beatrice Jahn-Schmid for fruitful discussions.
Key message
d Sensitizing allergens contain dominant T cell–reactive re-
gions, whereas nonsensitizing allergens do not.
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